A Phase 2 interventional study of Sildenafil citrate in Pre-eclampsia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 10 sites in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Pre-Eclampsia with a site in United Kingdom — 7 open to participants now, 9 under way, 1 of them phase 3. Pre-Eclampsia · United Kingdom.
Among the 29 studies in Pre-Eclampsia with a site in United Kingdom, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2004, is the only one in phase 2, and was the 1st registered.
918 studies on the registry are indexed under Pre-Eclampsia; 245 are open to participants now.
Browse Pre-Eclampsia studies →7 of the 29 studies in Pre-Eclampsia with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Oxford · Sites in United Kingdom
Ages 16+ · Women only · Healthy volunteers
University of Oxford · Sites in United Kingdom
Ages 18+ · Women only · Healthy volunteers
University of Oxford · Sites in United Kingdom
Ages 30–70 · Women only
University of Oxford · Sites in United Kingdom
Ages 18–45 · Women only · Healthy volunteers
Imperial College Healthcare NHS Trust · Sites in United Kingdom
Ages up to 6 mo · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 162 Pre-Eclampsia studies recruiting now, 81 (50%) set no upper age limit and 80 (49%) stop at 75 or younger; 18 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is below the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 202 across the 12 interventional studies, 150 across the 17 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 1 study filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
1 of the studies in Pre-Eclampsia with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06187012University of OxfordHypertension Explored in Long-term Postpartum Follow-up in Later Life | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Pre-Eclampsia with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the efficacy and safety of sildenafil citrate in the treatment of established pre-eclampsia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Primary endpoint is the time from randomization to delivery.
Individualised birth-weight ratio at delivery, Placental weight, Umbilical artery pulsatility index, Other indices of PET (incl. uric acid and maternal BP), Safety and toleration, Population PK, Fetal exposure (PK)
The record gives a start of Sep 2004 and a completion of Apr 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →